Gilead Sciences and Agenus Inc. have entered into an immuno-oncology (I-O) partnership for the development and commercialization of up to five novel immuno-oncology therapies.  Agenus will receive $150 million upon closing, which includes a $120 million upfront and a $30 million equity investment.  The agreement also includes approximately $1.7 billion in potential future fees and milestones. Gilead will receive worldwide exclusive rights to AGEN1423, which has an estimated IND filing by y...